218 related articles for article (PubMed ID: 15146248)
21. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
22. Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells.
Warncke M; Buchner M; Thaller G; Dodero A; Bulashevska A; Pfeifer D; Timmer J; Veelken H
Cancer Immunol Immunother; 2011 Jan; 60(1):49-60. PubMed ID: 20848095
[TBL] [Abstract][Full Text] [Related]
23. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.
Weng J; Cha SC; Matsueda S; Alatrash G; Popescu MS; Yi Q; Molldrem JJ; Wang M; Neelapu SS; Kwak LW
Clin Cancer Res; 2011 Sep; 17(18):5945-52. PubMed ID: 21813633
[TBL] [Abstract][Full Text] [Related]
24. Idiotype vaccine strategies for treatment of follicular lymphoma.
Mahaseth H; Brody JD; Sinha R; Shenoy PJ; Flowers CR
Future Oncol; 2011 Jan; 7(1):111-22. PubMed ID: 21174542
[TBL] [Abstract][Full Text] [Related]
25. Tumor-specific idiotype vaccines. III. Induction of T helper cells by anti-idiotype and tumor cells.
Raychaudhuri S; Saeki Y; Chen JJ; Kohler H
J Immunol; 1987 Sep; 139(6):2096-102. PubMed ID: 2442262
[TBL] [Abstract][Full Text] [Related]
26. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
Flowers CR
Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
[TBL] [Abstract][Full Text] [Related]
27. Delineation of the minimal hepatitis B surface antigen-specific B- and T-cell epitope contained within an anti-idiotype-derived pentadecapeptide.
Rajadhyaksha M; Thanavala Y
Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1575-9. PubMed ID: 7878021
[TBL] [Abstract][Full Text] [Related]
28. Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma.
Iurescia S; Fioretti D; Fazio VM; Rinaldi M
Curr Gene Ther; 2011 Oct; 11(5):414-22. PubMed ID: 21711228
[TBL] [Abstract][Full Text] [Related]
29. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma.
Berger CL; Longley J; Hanlon D; Girardi M; Edelson R
Ann N Y Acad Sci; 2001 Sep; 941():106-22. PubMed ID: 11594564
[TBL] [Abstract][Full Text] [Related]
30. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
[TBL] [Abstract][Full Text] [Related]
31. Determination of idiotype-specific T cells in idiotype-vaccinated mice.
Heyfets A; Haimovich J; Hollander N
Immunol Lett; 2002 Mar; 80(3):207-13. PubMed ID: 11803054
[TBL] [Abstract][Full Text] [Related]
32. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
33. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
34. Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera.
Cha SC; Kwak LW; Ruffini PA; Qin H; Neelapu S; Biragyn A
J Immunol Methods; 2006 May; 312(1-2):79-93. PubMed ID: 16631194
[TBL] [Abstract][Full Text] [Related]
35. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
36. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations.
Caspar CB; Levy S; Levy R
Blood; 1997 Nov; 90(9):3699-706. PubMed ID: 9345055
[TBL] [Abstract][Full Text] [Related]
37. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
McCormick AA; Reddy S; Reinl SJ; Cameron TI; Czerwinkski DK; Vojdani F; Hanley KM; Garger SJ; White EL; Novak J; Barrett J; Holtz RB; Tusé D; Levy R
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10131-6. PubMed ID: 18645180
[TBL] [Abstract][Full Text] [Related]
38. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
39. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
40. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma.
Nelson EL; Li X; Hsu FJ; Kwak LW; Levy R; Clayberger C; Krensky AM
Blood; 1996 Jul; 88(2):580-9. PubMed ID: 8695806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
